Xarelto Trial: Defense Wins Again in Dora Mingo vs. Bayer AG and Janssen R&D In Third Trial Loss for Plaintiffs

Xarelto Trial Update: Defense Wins Again in Dora Mingo vs. Bayer AG and Janssen R&D In Third Trial Loss for Plaintiffs

(Dora Mingo vs. Janssen Research & Development, LLC et al. Case No. 2:15-cv-03469)

 

JACKSON, Miss. – The Dora Mingo vs. Janssen and Bayer trial verdict was entered in favor of the defense this afternoon. This is the third trial verdict for defense in the Xeralto MDL 2592 bellwether trials, the verdict was returned in favor of the defendants not long after after closing arguments completed earlier today August 18, 2017.  Ms. Mingo a resident of Mississippi woman claims that Xarelto which was prescribed as a blood-thinner drug for treatment of a blood clot, caused her to suffer internal bleeding and anemia.

A jury of five men and four women were sitting in the U.S. District Court for the Southern District of Mississippi in front of visiting Judge Eldon Fallon, of the US District Court ED Louisiana, who heard closing arguments earlier today, and are now in deliberations.  The case relates to 69 year-old Dora Mingo of Summit, MS against the Bayer Companies and Janssen R&D and Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.

In previous back-to-back federal bellwether trials, juries have cleared the manufacturers of Xarelto of liability relating to claims that the drug caused internal bleeding, which plaintiff attorneys allege led to severe injuries or deaths in patients who used it.

The Food & Drug Administration (FDA) approved Xarelto in 2011 for prescription to patients suffering from a rhythmic heart disorder called atrial fibrillation and to prevent blood clots which can lead to heart attacks, strokes and pulmonary embolisms.

However, plaintiffs and their counsel charge Xarelto’s manufacturers with failing to properly warn patients that Xarelto use presented increased risks for cranial and gastrointestinal bleeding when taken once daily and not properly monitored.

Plaintiff counsel asserted a Prothrombin Time (PT) test, used to assess a patient for bleeding risks, was something Xarelto’s manufacturers didn’t inform and instruct doctors about. However, counsel for Xarelto’s manufacturers countered that the PT test isn’t scientifically reliable in their view.

Mingo, a grandmother and retired schoolteacher, was prescribed Xarelto in January 2015 for treatment of a blood clot in her leg. After taking Xarelto, Mingo alleges she suffered severe upper gastrointestinal bleeding and acute blood loss anemia.

As soon as the trial verdict is released Mass Tort Nexus will send update.

 

 

Share this Post: